China Pharma Holdings, Inc. (CPHI) 10-Year Financial Performance & Capital Metrics

CPHI • • Industrial / General

HealthcareSpecialty & Generic PharmaGeneric PharmaceuticalsStandard Generics

AboutChina Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.Show more

Revenue $5M -35.4%
EBITDA -$2M -107559.1%
Net Income -$5M -53.8%
EPS (Diluted) -0.27 +6.9%
Gross Margin -43.84% -993.6%
EBITDA Margin -43.52% -166190.8%
Operating Margin -101.32% -158.2%
Net Margin -104.58% -138.2%
ROE -62.31% -18.8%
ROIC -32.2% -69.1%
Debt/Equity 0.46 -25.4%
Interest Coverage -29.77 -260.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 13 (bottom 13%)
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 16.1% over 5 years
✗Shares diluted 64.8% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-14.67%

5Y-16.15%

3Y-22.27%

TTM13638711.97%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-13732288.05%

EPS CAGR

10Y-

5Y-

3Y-

TTM22.22%

ROCE

10Y Avg-22.61%

5Y Avg-35.1%

3Y Avg-41.93%

Latest-47.02%

Peer Comparison

Standard Generics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDYDr. Reddy's Laboratories Limited	10.9B	13.09	0.19	16.61%	17.13%	16.19%	100%	0.14
CPHIChina Pharma Holdings, Inc.	6.38M	1.27	-4.70	-35.41%	-86.15%	-76699.41%		0.46
TEVATeva Pharmaceutical Industries Limited	37.11B	32.35	-22.31	4.41%	4.24%	9.82%	5.52%	3.16
VTRSViatris Inc.	14.79B	12.84	-24.23	-4.46%	-26.13%	-24.26%	13.37%	0.77

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	20.35M	15.57M	13.21M	12.33M	10.92M	10.87M	9.64M	8.1M	7.01M	4.53M
Revenue Growth %	-0.08%	-0.23%	-0.15%	-0.07%	-0.11%	-0.01%	-0.11%	-0.16%	-0.13%	-0.35%
Cost of Goods Sold+	18.89M	12.35M	10.74M	10.36M	9.44M	8.91M	9.29M	8.6M	7.29M	6.51M
COGS % of Revenue	0.93%	0.79%	0.81%	0.84%	0.86%	0.82%	0.96%	1.06%	1.04%	1.44%
Gross Profit+	1.46M	3.22M	2.47M	1.97M	1.48M	1.95M	349.27K	-493.92K	-281.08K	-1.99M
Gross Margin %	0.07%	0.21%	0.19%	0.16%	0.14%	0.18%	0.04%	-0.06%	-0.04%	-0.44%
Gross Profit Growth %	-0.45%	1.2%	-0.23%	-0.2%	-0.25%	0.32%	-0.82%	-2.41%	0.43%	-6.06%
Operating Expenses+	-15.76M	-11.37M	-21.15M	-12.42M	4.87M	4.53M	3.21M	3.06M	2.47M	2.6M
OpEx % of Revenue	-0.77%	-0.73%	-1.6%	-1.01%	0.45%	0.42%	0.33%	0.38%	0.35%	0.57%
Selling, General & Admin	6.19M	6.3M	5.48M	5.17M	4.64M	4.04M	3.15M	2.96M	2.25M	2.31M
SG&A % of Revenue	0.3%	0.4%	0.41%	0.42%	0.42%	0.37%	0.33%	0.37%	0.32%	0.51%
Research & Development	961.9K	365.97K	90.47K	172.38K	229.64K	377.96K	318.96K	185.86K	240.08K	283.94K
R&D % of Revenue	0.05%	0.02%	0.01%	0.01%	0.02%	0.03%	0.03%	0.02%	0.03%	0.06%
Other Operating Expenses	0	0	4.83T	0	0	115.19K	-255.22K	-93.85K	-15.76K	5.7K
Operating Income+	-14.2M	-4.19M	-4.5M	-3.97M	-3.39M	-2.58M	-2.86M	-3.55M	-2.75M	-4.59M
Operating Margin %	-0.7%	-0.27%	-0.34%	-0.32%	-0.31%	-0.24%	-0.3%	-0.44%	-0.39%	-1.01%
Operating Income Growth %	0.61%	0.7%	-0.07%	0.12%	0.15%	0.24%	-0.11%	-0.24%	0.22%	-0.67%
EBITDA+	-17.79M	-1.12M	-1.2M	-709.62K	-460.78K	101.18K	227.31K	-848.44K	1.83K	-1.97M
EBITDA Margin %	-0.87%	-0.07%	-0.09%	-0.06%	-0.04%	0.01%	0.02%	-0.1%	0%	-0.44%
EBITDA Growth %	0.54%	0.94%	-0.08%	0.41%	0.35%	1.22%	1.25%	-4.73%	1%	-1075.59%
D&A (Non-Cash Add-back)	-3.6M	3.08M	3.29M	3.26M	2.93M	2.68M	3.09M	2.7M	2.75M	2.62M
EBIT	-14.18M	-8.02M	-18.62M	-10.41M	-20.38M	-2.57M	-2.86M	-3.54M	-2.75M	-4.58M
Net Interest Income+	-1.05M	-718.98K	-474.92K	-412.74K	-294.19K	-288.48K	-538.97K	-423.86K	-327K	-147.5K
Interest Income	119.92K	130.57K	64.41K	38.52K	27.53K	5.67K	3.04K	10.76K	6.6K	6.64K
Interest Expense	1.17M	849.56K	539.33K	451.26K	321.72K	294.16K	542K	434.62K	333.6K	154.14K
Other Income/Expense	-1.15M	-4.68M	-14.66M	-6.89M	-17.31M	-288.48K	-538.97K	-423.86K	-327K	-147.5K
Pretax Income+	-15.35M	-8.87M	-19.15M	-10.86M	-20.7M	-2.87M	-3.4M	-3.97M	-3.08M	-4.74M
Pretax Margin %	-0.75%	-0.57%	-1.45%	-0.88%	-1.9%	-0.26%	-0.35%	-0.49%	-0.44%	-1.05%
Income Tax+	60.44K	308.18K	122.63K	-109.99K	0	0	0	0	0	0
Effective Tax Rate %	1%	1.03%	1.01%	0.99%	1%	1%	1%	1%	1%	1%
Net Income+	-15.41M	-9.18M	-19.28M	-10.75M	-20.7M	-2.87M	-3.4M	-3.97M	-3.08M	-4.74M
Net Margin %	-0.76%	-0.59%	-1.46%	-0.87%	-1.9%	-0.26%	-0.35%	-0.49%	-0.44%	-1.05%
Net Income Growth %	0.41%	0.4%	-1.1%	0.44%	-0.93%	0.86%	-0.19%	-0.17%	0.23%	-0.54%
Net Income (Continuing)	-15.41M	-9.18M	-19.28M	-10.75M	-20.7M	-2.87M	-3.4M	-3.97M	-3.08M	-4.74M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.54	-2.11	-4.42	-2.47	-4.82	-0.72	-0.85	-1.94	-0.29	-0.27
EPS Growth %	0.41%	0.4%	-1.09%	0.44%	-0.95%	0.85%	-0.18%	-1.28%	0.85%	0.07%
EPS (Basic)	-3.54	-2.11	-4.42	-2.47	-4.82	-0.72	-0.85	-1.94	-0.29	-0.27
Diluted Shares Outstanding	4.61M	4.61M	4.61M	4.61M	4.61M	4.61M	4.61M	5.26M	10.6M	17.46M
Basic Shares Outstanding	4.61M	4.61M	4.61M	4.61M	4.61M	4.61M	4.61M	5.26M	10.6M	17.46M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	24.96M	17.52M	12.29M	8.75M	5.58M	5.32M	9.09M	5.96M	6M	3.27M
Cash & Short-Term Investments	6.25M	2.67M	2.03M	1.19M	1.07M	957.65K	4.86M	2.03M	1.42M	626.88K
Cash Only	6.25M	2.67M	2.03M	1.19M	1.07M	957.65K	4.86M	2.03M	1.42M	626.88K
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	5.46M	4.22M	2.46M	1.09M	682.01K	529.54K	835.4K	464.45K	728.31K	281.07K
Days Sales Outstanding	98.01	99.02	67.85	32.18	22.79	17.79	31.62	20.92	37.91	22.65
Inventory	9.66M	7.31M	6.41M	5.05M	3.59M	3.71M	3.34M	2.95M	3.73M	2.27M
Days Inventory Outstanding	186.74	216.04	217.67	178.17	138.74	151.72	131.18	125.14	186.82	126.97
Other Current Assets	0	1.09M	709.8K	1.27M	155.66K	55.97K	471	444.64K	0	0
Total Non-Current Assets+	72.26M	61M	47.66M	36.63M	16.66M	15.8M	13.56M	11.82M	10.47M	11.62M
Property, Plant & Equipment	28.96M	24.56M	23.11M	18.88M	16.05M	15.18M	12.97M	9.61M	6.82M	4.53M
Fixed Asset Turnover	0.70x	0.63x	0.57x	0.65x	0.68x	0.72x	0.74x	0.84x	1.03x	1.00x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.28M	940.33K	831.77K	676.05K	609.37K	613.83K	589.62K	2.21M	3.65M	7.09M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	42.03M	35.5M	23.72M	17.07M	0	0	0	0	0	0
Total Assets+	97.22M	78.52M	59.95M	45.38M	22.24M	21.12M	22.65M	17.78M	16.47M	14.89M
Asset Turnover	0.21x	0.20x	0.22x	0.27x	0.49x	0.51x	0.43x	0.46x	0.43x	0.30x
Asset Growth %	-0.26%	-0.19%	-0.24%	-0.24%	-0.51%	-0.05%	0.07%	-0.21%	-0.07%	-0.1%
Total Current Liabilities+	12.79M	10.4M	9.23M	10.05M	10.05M	11.4M	10.51M	12.74M	6.82M	5.02M
Accounts Payable	2.44M	3.06M	1.14M	1.06M	1.37M	1.23M	926.75K	667.08K	966.42K	225.11K
Days Payables Outstanding	47.14	90.43	38.77	37.39	52.82	50.56	36.4	28.32	48.37	12.61
Short-Term Debt	6.16M	2.53M	3.02M	3.46M	4.33M	6.47M	7.11M	8.72M	3.1M	2.16M
Deferred Revenue (Current)	595.68K	811.23K	581.13K	525.65K	505.4K	719.79K	210.03K	520.29K	90.51K	162.21K
Other Current Liabilities	0	0	0	0	0	297.49K	327.03K	372.58K	1.26M	1.59M
Current Ratio	1.95x	1.68x	1.33x	0.87x	0.56x	0.47x	0.86x	0.47x	0.88x	0.65x
Quick Ratio	1.20x	0.98x	0.64x	0.37x	0.20x	0.14x	0.55x	0.24x	0.33x	0.20x
Cash Conversion Cycle	237.61	224.63	246.75	172.95	108.71	118.95	126.4	117.74	176.36	137.01
Total Non-Current Liabilities+	11.79M	9.21M	7.65M	5.13M	2.95M	1.71M	6.12M	754.7K	2.19M	2.12M
Long-Term Debt	10.78M	8.64M	6.92M	4.36M	2.15M	904.23K	5.25M	0	1.41M	1.39M
Capital Lease Obligations	0	0	0	0	48.7K	0	44.18K	0	39.91K	0
Deferred Tax Liabilities	296.89K	572.35K	738.17K	764.37K	753.44K	805.56K	824.41K	754.7K	742.11K	731.2K
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	24.58M	19.61M	16.88M	15.18M	13M	13.11M	16.63M	13.49M	9.01M	7.14M
Total Debt+	16.95M	11.17M	9.93M	7.82M	6.62M	7.43M	12.49M	8.76M	4.63M	3.59M
Net Debt	10.7M	8.5M	7.9M	6.63M	5.55M	6.47M	7.63M	6.73M	3.21M	2.96M
Debt / Equity	0.23x	0.19x	0.23x	0.26x	0.72x	0.93x	2.08x	2.04x	0.62x	0.46x
Debt / EBITDA	-	-	-	-	-	73.42x	54.94x	-	2526.73x	-
Net Debt / EBITDA	-	-	-	-	-	63.95x	33.56x	-	1750.37x	-
Interest Coverage	-12.18x	-4.94x	-8.34x	-8.79x	-10.54x	-8.76x	-5.28x	-8.17x	-8.25x	-29.77x
Total Equity+	72.64M	58.91M	43.07M	30.2M	9.24M	8M	6.02M	4.29M	7.45M	7.75M
Equity Growth %	-0.32%	-0.19%	-0.27%	-0.3%	-0.69%	-0.13%	-0.25%	-0.29%	0.74%	0.04%
Book Value per Share	15.75	12.77	9.34	6.55	2.00	1.74	1.30	0.82	0.70	0.44
Total Shareholders' Equity	72.64M	58.91M	43.07M	30.2M	9.24M	8M	6.02M	4.29M	7.45M	7.75M
Common Stock	43.58K	43.58K	43.58K	43.58K	43.58K	45.58K	47.34K	74.91K	10.63K	32.62K
Retained Earnings	33.94M	24.76M	5.48M	-5.27M	-25.97M	-28.84M	-32.24M	-36.21M	-39.29M	-44.03M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	15.07M	10.52M	13.96M	11.84M	11.58M	12.35M	12.56M	11.57M	11.45M	11.32M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	3.35M	2.9M	841.22K	1.26M	608.31K	-42.26K	-249.84K	-409.55K	-699.69K	-466.36K
Operating CF Margin %	0.16%	0.19%	0.06%	0.1%	0.06%	-0%	-0.03%	-0.05%	-0.1%	-0.1%
Operating CF Growth %	-0.27%	-0.14%	-0.71%	0.49%	-0.52%	-1.07%	-4.91%	-0.64%	-0.71%	0.33%
Net Income	-15.41M	-9.18M	-19.28M	-10.75M	-20.7M	-2.87M	-3.4M	-3.97M	-3.08M	-4.74M
Depreciation & Amortization	3.6M	3.08M	3.29M	3.26M	2.93M	2.68M	3.09M	2.7M	2.75M	2.62M
Stock-Based Compensation	0	0	0	0	0	0	15.24K	78.27K	0	0
Deferred Taxes	60.44K	308.18K	122.63K	68.42K	0	0	0	0	0	0
Other Non-Cash Items	-1.74M	3.96M	15.7M	8.04M	17.27M	115.19K	-5.21K	-93.85K	21.65K	456.44K
Working Capital Changes	4.65M	3.64M	1.01M	642.25K	1.11M	29.86K	51.79K	878.34K	-396.18K	1.2M
Change in Receivables	319.9K	-172.25K	51.02K	99.4K	-1.2M	-733.45K	-545.53K	-170.19K	-938.02K	-197.71K
Change in Inventory	5.16M	2.73M	1.72M	688.85K	2M	807.59K	1.01M	689.1K	-17.06K	1.61M
Change in Payables	601.47K	815.2K	-2.05M	-16.44K	324.18K	-214.01K	-332.78K	-187.73K	312.05K	-733.92K
Cash from Investing+	-1.9M	-193.4K	-136.48K	-51.15K	-136K	-867.31K	-438.06K	-401.96K	-11.52K	-291.72K
Capital Expenditures	-2.32M	-193.4K	-136.48K	-51.15K	-136K	-867.31K	-438.06K	-401.96K	-11.52K	-38.41K
CapEx % of Revenue	0.11%	0.01%	0.01%	0%	0.01%	0.08%	0.05%	0.05%	0%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	423.69K	0	0	0	0	0	0	0	0	-253.31K
Cash from Financing+	0	-6.02M	-1.48M	-1.98M	-1.73M	624.18K	4.6M	-1.77M	73.14K	27.35K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	0	-223.01K	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	1.03M	2.7M	704.74K	1.21M	472.31K	-909.57K	-687.89K	-811.51K	-711.2K	-758.08K
FCF Margin %	0.05%	0.17%	0.05%	0.1%	0.04%	-0.08%	-0.07%	-0.1%	-0.1%	-0.17%
FCF Growth %	1.81%	1.62%	-0.74%	0.71%	-0.61%	-2.93%	0.24%	-0.18%	0.12%	-0.07%
FCF per Share	0.22	0.59	0.15	0.26	0.10	-0.20	-0.15	-0.15	-0.07	-0.04
FCF Conversion (FCF/Net Income)	-0.22x	-0.32x	-0.04x	-0.12x	-0.03x	0.01x	0.07x	0.10x	0.23x	0.10x
Interest Paid	1.15M	836.01K	525.79K	588.19K	299.16K	237.53K	218.23K	141.8K	92.44K	86.77K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-17.22%	-13.96%	-37.81%	-29.34%	-104.99%	-33.25%	-48.49%	-77.08%	-52.43%	-62.31%
Return on Invested Capital (ROIC)	-10.53%	-4.17%	-5.7%	-6.78%	-9.85%	-13.22%	-15.26%	-21.58%	-19.04%	-32.2%
Gross Margin	7.2%	20.67%	18.68%	16.02%	13.57%	17.97%	3.62%	-6.09%	-4.01%	-43.84%
Net Margin	-75.7%	-58.97%	-145.91%	-87.18%	-189.51%	-26.38%	-35.26%	-49.02%	-43.91%	-104.58%
Debt / Equity	0.23x	0.19x	0.23x	0.26x	0.72x	0.93x	2.08x	2.04x	0.62x	0.46x
Interest Coverage	-12.18x	-4.94x	-8.34x	-8.79x	-10.54x	-8.76x	-5.28x	-8.17x	-8.25x	-29.77x
FCF Conversion	-0.22x	-0.32x	-0.04x	-0.12x	-0.03x	0.01x	0.07x	0.10x	0.23x	0.10x
Revenue Growth	-8.05%	-23.49%	-15.15%	-6.67%	-11.41%	-0.53%	-11.27%	-15.95%	-13.48%	-35.41%

Revenue by Segment

	2020	2021
DomesticPharmaceuticalsMember	-	9.64M
DomesticPharmaceuticalsMember Growth	-	-
Domestic Pharmaceuticals	9.13M	-
Domestic Pharmaceuticals Growth	-	-
COVID 19 Testers	1.73M	-
COVID 19 Testers Growth	-	-

Frequently Asked Questions

Growth & Financials

China Pharma Holdings, Inc. (CPHI) reported $756.22B in revenue for fiscal year 2024. This represents a 931587% increase from $81.2M in 2011.

China Pharma Holdings, Inc. (CPHI) saw revenue decline by 35.4% over the past year.

China Pharma Holdings, Inc. (CPHI) reported a net loss of $651.48B for fiscal year 2024.

Dividend & Returns

China Pharma Holdings, Inc. (CPHI) has a return on equity (ROE) of -62.3%. Negative ROE indicates the company is unprofitable.

China Pharma Holdings, Inc. (CPHI) had negative free cash flow of $0.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

China Pharma Holdings, Inc. (CPHI) 10-Year Financial Performance & Capital Metrics

CPHI • • Industrial / General

HealthcareSpecialty & Generic PharmaGeneric PharmaceuticalsStandard Generics

Revenue $5M -35.4%
EBITDA -$2M -107559.1%
Net Income -$5M -53.8%
EPS (Diluted) -0.27 +6.9%
Gross Margin -43.84% -993.6%
EBITDA Margin -43.52% -166190.8%
Operating Margin -101.32% -158.2%
Net Margin -104.58% -138.2%
ROE -62.31% -18.8%
ROIC -32.2% -69.1%
Debt/Equity 0.46 -25.4%
Interest Coverage -29.77 -260.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 13 (bottom 13%)
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 16.1% over 5 years
✗Shares diluted 64.8% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-14.67%

5Y-16.15%

3Y-22.27%

TTM13638711.97%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-13732288.05%

EPS CAGR

10Y-

5Y-

3Y-

TTM22.22%

ROCE

10Y Avg-22.61%

5Y Avg-35.1%

3Y Avg-41.93%

Latest-47.02%

Peer Comparison

Standard Generics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDYDr. Reddy's Laboratories Limited	10.9B	13.09	0.19	16.61%	17.13%	16.19%	100%	0.14
CPHIChina Pharma Holdings, Inc.	6.38M	1.27	-4.70	-35.41%	-86.15%	-76699.41%		0.46
TEVATeva Pharmaceutical Industries Limited	37.11B	32.35	-22.31	4.41%	4.24%	9.82%	5.52%	3.16
VTRSViatris Inc.	14.79B	12.84	-24.23	-4.46%	-26.13%	-24.26%	13.37%	0.77

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	20.35M	15.57M	13.21M	12.33M	10.92M	10.87M	9.64M	8.1M	7.01M	4.53M
Revenue Growth %	-0.08%	-0.23%	-0.15%	-0.07%	-0.11%	-0.01%	-0.11%	-0.16%	-0.13%	-0.35%
Cost of Goods Sold+	18.89M	12.35M	10.74M	10.36M	9.44M	8.91M	9.29M	8.6M	7.29M	6.51M
COGS % of Revenue	0.93%	0.79%	0.81%	0.84%	0.86%	0.82%	0.96%	1.06%	1.04%	1.44%
Gross Profit+	1.46M	3.22M	2.47M	1.97M	1.48M	1.95M	349.27K	-493.92K	-281.08K	-1.99M
Gross Margin %	0.07%	0.21%	0.19%	0.16%	0.14%	0.18%	0.04%	-0.06%	-0.04%	-0.44%
Gross Profit Growth %	-0.45%	1.2%	-0.23%	-0.2%	-0.25%	0.32%	-0.82%	-2.41%	0.43%	-6.06%
Operating Expenses+	-15.76M	-11.37M	-21.15M	-12.42M	4.87M	4.53M	3.21M	3.06M	2.47M	2.6M
OpEx % of Revenue	-0.77%	-0.73%	-1.6%	-1.01%	0.45%	0.42%	0.33%	0.38%	0.35%	0.57%
Selling, General & Admin	6.19M	6.3M	5.48M	5.17M	4.64M	4.04M	3.15M	2.96M	2.25M	2.31M
SG&A % of Revenue	0.3%	0.4%	0.41%	0.42%	0.42%	0.37%	0.33%	0.37%	0.32%	0.51%
Research & Development	961.9K	365.97K	90.47K	172.38K	229.64K	377.96K	318.96K	185.86K	240.08K	283.94K
R&D % of Revenue	0.05%	0.02%	0.01%	0.01%	0.02%	0.03%	0.03%	0.02%	0.03%	0.06%
Other Operating Expenses	0	0	4.83T	0	0	115.19K	-255.22K	-93.85K	-15.76K	5.7K
Operating Income+	-14.2M	-4.19M	-4.5M	-3.97M	-3.39M	-2.58M	-2.86M	-3.55M	-2.75M	-4.59M
Operating Margin %	-0.7%	-0.27%	-0.34%	-0.32%	-0.31%	-0.24%	-0.3%	-0.44%	-0.39%	-1.01%
Operating Income Growth %	0.61%	0.7%	-0.07%	0.12%	0.15%	0.24%	-0.11%	-0.24%	0.22%	-0.67%
EBITDA+	-17.79M	-1.12M	-1.2M	-709.62K	-460.78K	101.18K	227.31K	-848.44K	1.83K	-1.97M
EBITDA Margin %	-0.87%	-0.07%	-0.09%	-0.06%	-0.04%	0.01%	0.02%	-0.1%	0%	-0.44%
EBITDA Growth %	0.54%	0.94%	-0.08%	0.41%	0.35%	1.22%	1.25%	-4.73%	1%	-1075.59%
D&A (Non-Cash Add-back)	-3.6M	3.08M	3.29M	3.26M	2.93M	2.68M	3.09M	2.7M	2.75M	2.62M
EBIT	-14.18M	-8.02M	-18.62M	-10.41M	-20.38M	-2.57M	-2.86M	-3.54M	-2.75M	-4.58M
Net Interest Income+	-1.05M	-718.98K	-474.92K	-412.74K	-294.19K	-288.48K	-538.97K	-423.86K	-327K	-147.5K
Interest Income	119.92K	130.57K	64.41K	38.52K	27.53K	5.67K	3.04K	10.76K	6.6K	6.64K
Interest Expense	1.17M	849.56K	539.33K	451.26K	321.72K	294.16K	542K	434.62K	333.6K	154.14K
Other Income/Expense	-1.15M	-4.68M	-14.66M	-6.89M	-17.31M	-288.48K	-538.97K	-423.86K	-327K	-147.5K
Pretax Income+	-15.35M	-8.87M	-19.15M	-10.86M	-20.7M	-2.87M	-3.4M	-3.97M	-3.08M	-4.74M
Pretax Margin %	-0.75%	-0.57%	-1.45%	-0.88%	-1.9%	-0.26%	-0.35%	-0.49%	-0.44%	-1.05%
Income Tax+	60.44K	308.18K	122.63K	-109.99K	0	0	0	0	0	0
Effective Tax Rate %	1%	1.03%	1.01%	0.99%	1%	1%	1%	1%	1%	1%
Net Income+	-15.41M	-9.18M	-19.28M	-10.75M	-20.7M	-2.87M	-3.4M	-3.97M	-3.08M	-4.74M
Net Margin %	-0.76%	-0.59%	-1.46%	-0.87%	-1.9%	-0.26%	-0.35%	-0.49%	-0.44%	-1.05%
Net Income Growth %	0.41%	0.4%	-1.1%	0.44%	-0.93%	0.86%	-0.19%	-0.17%	0.23%	-0.54%
Net Income (Continuing)	-15.41M	-9.18M	-19.28M	-10.75M	-20.7M	-2.87M	-3.4M	-3.97M	-3.08M	-4.74M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.54	-2.11	-4.42	-2.47	-4.82	-0.72	-0.85	-1.94	-0.29	-0.27
EPS Growth %	0.41%	0.4%	-1.09%	0.44%	-0.95%	0.85%	-0.18%	-1.28%	0.85%	0.07%
EPS (Basic)	-3.54	-2.11	-4.42	-2.47	-4.82	-0.72	-0.85	-1.94	-0.29	-0.27
Diluted Shares Outstanding	4.61M	4.61M	4.61M	4.61M	4.61M	4.61M	4.61M	5.26M	10.6M	17.46M
Basic Shares Outstanding	4.61M	4.61M	4.61M	4.61M	4.61M	4.61M	4.61M	5.26M	10.6M	17.46M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	24.96M	17.52M	12.29M	8.75M	5.58M	5.32M	9.09M	5.96M	6M	3.27M
Cash & Short-Term Investments	6.25M	2.67M	2.03M	1.19M	1.07M	957.65K	4.86M	2.03M	1.42M	626.88K
Cash Only	6.25M	2.67M	2.03M	1.19M	1.07M	957.65K	4.86M	2.03M	1.42M	626.88K
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	5.46M	4.22M	2.46M	1.09M	682.01K	529.54K	835.4K	464.45K	728.31K	281.07K
Days Sales Outstanding	98.01	99.02	67.85	32.18	22.79	17.79	31.62	20.92	37.91	22.65
Inventory	9.66M	7.31M	6.41M	5.05M	3.59M	3.71M	3.34M	2.95M	3.73M	2.27M
Days Inventory Outstanding	186.74	216.04	217.67	178.17	138.74	151.72	131.18	125.14	186.82	126.97
Other Current Assets	0	1.09M	709.8K	1.27M	155.66K	55.97K	471	444.64K	0	0
Total Non-Current Assets+	72.26M	61M	47.66M	36.63M	16.66M	15.8M	13.56M	11.82M	10.47M	11.62M
Property, Plant & Equipment	28.96M	24.56M	23.11M	18.88M	16.05M	15.18M	12.97M	9.61M	6.82M	4.53M
Fixed Asset Turnover	0.70x	0.63x	0.57x	0.65x	0.68x	0.72x	0.74x	0.84x	1.03x	1.00x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.28M	940.33K	831.77K	676.05K	609.37K	613.83K	589.62K	2.21M	3.65M	7.09M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	42.03M	35.5M	23.72M	17.07M	0	0	0	0	0	0
Total Assets+	97.22M	78.52M	59.95M	45.38M	22.24M	21.12M	22.65M	17.78M	16.47M	14.89M
Asset Turnover	0.21x	0.20x	0.22x	0.27x	0.49x	0.51x	0.43x	0.46x	0.43x	0.30x
Asset Growth %	-0.26%	-0.19%	-0.24%	-0.24%	-0.51%	-0.05%	0.07%	-0.21%	-0.07%	-0.1%
Total Current Liabilities+	12.79M	10.4M	9.23M	10.05M	10.05M	11.4M	10.51M	12.74M	6.82M	5.02M
Accounts Payable	2.44M	3.06M	1.14M	1.06M	1.37M	1.23M	926.75K	667.08K	966.42K	225.11K
Days Payables Outstanding	47.14	90.43	38.77	37.39	52.82	50.56	36.4	28.32	48.37	12.61
Short-Term Debt	6.16M	2.53M	3.02M	3.46M	4.33M	6.47M	7.11M	8.72M	3.1M	2.16M
Deferred Revenue (Current)	595.68K	811.23K	581.13K	525.65K	505.4K	719.79K	210.03K	520.29K	90.51K	162.21K
Other Current Liabilities	0	0	0	0	0	297.49K	327.03K	372.58K	1.26M	1.59M
Current Ratio	1.95x	1.68x	1.33x	0.87x	0.56x	0.47x	0.86x	0.47x	0.88x	0.65x
Quick Ratio	1.20x	0.98x	0.64x	0.37x	0.20x	0.14x	0.55x	0.24x	0.33x	0.20x
Cash Conversion Cycle	237.61	224.63	246.75	172.95	108.71	118.95	126.4	117.74	176.36	137.01
Total Non-Current Liabilities+	11.79M	9.21M	7.65M	5.13M	2.95M	1.71M	6.12M	754.7K	2.19M	2.12M
Long-Term Debt	10.78M	8.64M	6.92M	4.36M	2.15M	904.23K	5.25M	0	1.41M	1.39M
Capital Lease Obligations	0	0	0	0	48.7K	0	44.18K	0	39.91K	0
Deferred Tax Liabilities	296.89K	572.35K	738.17K	764.37K	753.44K	805.56K	824.41K	754.7K	742.11K	731.2K
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	24.58M	19.61M	16.88M	15.18M	13M	13.11M	16.63M	13.49M	9.01M	7.14M
Total Debt+	16.95M	11.17M	9.93M	7.82M	6.62M	7.43M	12.49M	8.76M	4.63M	3.59M
Net Debt	10.7M	8.5M	7.9M	6.63M	5.55M	6.47M	7.63M	6.73M	3.21M	2.96M
Debt / Equity	0.23x	0.19x	0.23x	0.26x	0.72x	0.93x	2.08x	2.04x	0.62x	0.46x
Debt / EBITDA	-	-	-	-	-	73.42x	54.94x	-	2526.73x	-
Net Debt / EBITDA	-	-	-	-	-	63.95x	33.56x	-	1750.37x	-
Interest Coverage	-12.18x	-4.94x	-8.34x	-8.79x	-10.54x	-8.76x	-5.28x	-8.17x	-8.25x	-29.77x
Total Equity+	72.64M	58.91M	43.07M	30.2M	9.24M	8M	6.02M	4.29M	7.45M	7.75M
Equity Growth %	-0.32%	-0.19%	-0.27%	-0.3%	-0.69%	-0.13%	-0.25%	-0.29%	0.74%	0.04%
Book Value per Share	15.75	12.77	9.34	6.55	2.00	1.74	1.30	0.82	0.70	0.44
Total Shareholders' Equity	72.64M	58.91M	43.07M	30.2M	9.24M	8M	6.02M	4.29M	7.45M	7.75M
Common Stock	43.58K	43.58K	43.58K	43.58K	43.58K	45.58K	47.34K	74.91K	10.63K	32.62K
Retained Earnings	33.94M	24.76M	5.48M	-5.27M	-25.97M	-28.84M	-32.24M	-36.21M	-39.29M	-44.03M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	15.07M	10.52M	13.96M	11.84M	11.58M	12.35M	12.56M	11.57M	11.45M	11.32M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	3.35M	2.9M	841.22K	1.26M	608.31K	-42.26K	-249.84K	-409.55K	-699.69K	-466.36K
Operating CF Margin %	0.16%	0.19%	0.06%	0.1%	0.06%	-0%	-0.03%	-0.05%	-0.1%	-0.1%
Operating CF Growth %	-0.27%	-0.14%	-0.71%	0.49%	-0.52%	-1.07%	-4.91%	-0.64%	-0.71%	0.33%
Net Income	-15.41M	-9.18M	-19.28M	-10.75M	-20.7M	-2.87M	-3.4M	-3.97M	-3.08M	-4.74M
Depreciation & Amortization	3.6M	3.08M	3.29M	3.26M	2.93M	2.68M	3.09M	2.7M	2.75M	2.62M
Stock-Based Compensation	0	0	0	0	0	0	15.24K	78.27K	0	0
Deferred Taxes	60.44K	308.18K	122.63K	68.42K	0	0	0	0	0	0
Other Non-Cash Items	-1.74M	3.96M	15.7M	8.04M	17.27M	115.19K	-5.21K	-93.85K	21.65K	456.44K
Working Capital Changes	4.65M	3.64M	1.01M	642.25K	1.11M	29.86K	51.79K	878.34K	-396.18K	1.2M
Change in Receivables	319.9K	-172.25K	51.02K	99.4K	-1.2M	-733.45K	-545.53K	-170.19K	-938.02K	-197.71K
Change in Inventory	5.16M	2.73M	1.72M	688.85K	2M	807.59K	1.01M	689.1K	-17.06K	1.61M
Change in Payables	601.47K	815.2K	-2.05M	-16.44K	324.18K	-214.01K	-332.78K	-187.73K	312.05K	-733.92K
Cash from Investing+	-1.9M	-193.4K	-136.48K	-51.15K	-136K	-867.31K	-438.06K	-401.96K	-11.52K	-291.72K
Capital Expenditures	-2.32M	-193.4K	-136.48K	-51.15K	-136K	-867.31K	-438.06K	-401.96K	-11.52K	-38.41K
CapEx % of Revenue	0.11%	0.01%	0.01%	0%	0.01%	0.08%	0.05%	0.05%	0%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	423.69K	0	0	0	0	0	0	0	0	-253.31K
Cash from Financing+	0	-6.02M	-1.48M	-1.98M	-1.73M	624.18K	4.6M	-1.77M	73.14K	27.35K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	0	-223.01K	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	1.03M	2.7M	704.74K	1.21M	472.31K	-909.57K	-687.89K	-811.51K	-711.2K	-758.08K
FCF Margin %	0.05%	0.17%	0.05%	0.1%	0.04%	-0.08%	-0.07%	-0.1%	-0.1%	-0.17%
FCF Growth %	1.81%	1.62%	-0.74%	0.71%	-0.61%	-2.93%	0.24%	-0.18%	0.12%	-0.07%
FCF per Share	0.22	0.59	0.15	0.26	0.10	-0.20	-0.15	-0.15	-0.07	-0.04
FCF Conversion (FCF/Net Income)	-0.22x	-0.32x	-0.04x	-0.12x	-0.03x	0.01x	0.07x	0.10x	0.23x	0.10x
Interest Paid	1.15M	836.01K	525.79K	588.19K	299.16K	237.53K	218.23K	141.8K	92.44K	86.77K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-17.22%	-13.96%	-37.81%	-29.34%	-104.99%	-33.25%	-48.49%	-77.08%	-52.43%	-62.31%
Return on Invested Capital (ROIC)	-10.53%	-4.17%	-5.7%	-6.78%	-9.85%	-13.22%	-15.26%	-21.58%	-19.04%	-32.2%
Gross Margin	7.2%	20.67%	18.68%	16.02%	13.57%	17.97%	3.62%	-6.09%	-4.01%	-43.84%
Net Margin	-75.7%	-58.97%	-145.91%	-87.18%	-189.51%	-26.38%	-35.26%	-49.02%	-43.91%	-104.58%
Debt / Equity	0.23x	0.19x	0.23x	0.26x	0.72x	0.93x	2.08x	2.04x	0.62x	0.46x
Interest Coverage	-12.18x	-4.94x	-8.34x	-8.79x	-10.54x	-8.76x	-5.28x	-8.17x	-8.25x	-29.77x
FCF Conversion	-0.22x	-0.32x	-0.04x	-0.12x	-0.03x	0.01x	0.07x	0.10x	0.23x	0.10x
Revenue Growth	-8.05%	-23.49%	-15.15%	-6.67%	-11.41%	-0.53%	-11.27%	-15.95%	-13.48%	-35.41%

Revenue by Segment

	2020	2021
DomesticPharmaceuticalsMember	-	9.64M
DomesticPharmaceuticalsMember Growth	-	-
Domestic Pharmaceuticals	9.13M	-
Domestic Pharmaceuticals Growth	-	-
COVID 19 Testers	1.73M	-
COVID 19 Testers Growth	-	-

Frequently Asked Questions

Growth & Financials

China Pharma Holdings, Inc. (CPHI) reported $756.22B in revenue for fiscal year 2024. This represents a 931587% increase from $81.2M in 2011.

China Pharma Holdings, Inc. (CPHI) saw revenue decline by 35.4% over the past year.

China Pharma Holdings, Inc. (CPHI) reported a net loss of $651.48B for fiscal year 2024.

Dividend & Returns

China Pharma Holdings, Inc. (CPHI) has a return on equity (ROE) of -62.3%. Negative ROE indicates the company is unprofitable.

China Pharma Holdings, Inc. (CPHI) had negative free cash flow of $0.1M in fiscal year 2024, likely due to heavy capital investments.